ID
25057
Beskrivning
Study ID: 101468/228 Clinical Study ID: 101468/228 Study Title:A two year Phase IIIb randomised, multicenter, double-blind, SINEMET controlled, parallel group, flexible dose study, to assess the effectiveness of controlled release ropinirole add-on therapy to L-dopa at increasing the time to onset of dyskinesia in Parkinson's disease subjects. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00363727 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication : Dyskinesias; Parkinson Disease; Parkinson's Disease Study part: PGx-Pharamacogenetic research.
Nyckelord
Versioner (2)
- 2017-08-25 2017-08-25 -
- 2017-09-08 2017-09-08 -
Rättsinnehavare
GlaxoSmithKline
Uppladdad den
25 augusti 2017
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
PGx-Pharamacogenetic research GSK study Dyskinesia in Parkinson's disease NCT00363727
PGx-Pharamacogenetic research study Dyskinesia in Parkinson's disease NCT00363727
Beskrivning
Consent for PGx-Pharamacogenetic research
Beskrivning
The question "Has informed consent been obtained for PGx-Pharmacogenetic research?" should be completed at either Visit 6, Early Withdrawal, or Follow-Up Visit. If the question is answered No, check one box for reason and do not complete the remainder of the page.
Datatyp
boolean
Beskrivning
date consent PGx-Pharmacogenetic research
Datatyp
date
Beskrivning
reason consent unavailable
Datatyp
text
Beskrivning
reason consent unavailable specification
Datatyp
text
Beskrivning
Blood sample collection (DNA)
Beskrivning
Withdrawal of consent
Beskrivning
The question "Has the subject withdrawn consent for PGx-Pharmacogenetic research?" must be completed immediately if the subject withdraws consent. Otherwise, it must be completed when the subject leaves the study. It must be completed for all subjects for whom informed consent was obtained for PGx-Pharmacogenetic research. If consent is withdrawn, a request for destruction must be made and Blood Sample Destruction section below completed.
Datatyp
boolean
Beskrivning
Blood sample destruction
Beskrivning
Do not complete this section if a blood sample was not collected. The question "Has a request been made for sample destruction?" must be completed immediately if there is a request for sample destruction. Otherwise, it must be completed when the subject leaves the study. It must be completed for all subjects for whom a blood sample was obtained for PGx-Pharmacogenetic research.
Datatyp
boolean
Beskrivning
Blood sample destruction reason
Datatyp
text
Beskrivning
Blood sample destruction reason specification
Datatyp
text